Thymosin Alpha-1 vs ARA-290
Side-by-side comparison of key properties, dosing, and research.
Immune SupportAnti-Aging & Longevity
Thymosin Alpha-1Immune SupportRecovery & Repair
ARA-290- Summary
- Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide derived from the thymus gland. It is a powerful immune modulator approved in many countries for treating chronic hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
- ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
- Half-Life
- 2–3 hours
- ~2–4 hours (SC administration)
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 0.8–1.6 mg
- 4 mg (fixed dose)
- Frequency
- Twice weekly
- Once daily
- Key Benefits
- Enhances T-cell and NK cell activity
- Supports recovery from viral and bacterial infections
- May reduce inflammation systemically
- Supports healthy aging and immune resilience
- Improves vaccine response
- Supports liver health
- May help with chronic fatigue syndrome and post-viral conditions
- Approved in multiple countries for hepatitis B and C treatment
- Reduces neuropathic pain from small fiber neuropathy
- Anti-inflammatory without immune suppression
- Tissue protection after ischemia/reperfusion injury
- Promotes nerve fiber regeneration
- Improves symptoms of sarcoidosis-associated neuropathy
- May reduce insulin resistance and improve metabolic health
- Shown to improve autonomic neuropathy symptoms
- Side Effects
- Injection site irritation
- Mild flu-like symptoms initially (immune activation)
- Fatigue (rare)
- Injection site reactions
- Mild fatigue at initiation
- Transient warm sensation post-injection
- Rare: mild headache
- Stacks With
- —
- —